21世纪经济报道记者韩利明上海报道日前,全球仿制药巨头梯瓦(Teva)在2025年第一季度财报电话会议中,披露了向领先生物制药公司转型的规划,目标是在对业务增长及产品管线再投资后,到2027年实现约7亿美元净节省,同时抵消来那度胺(瑞复美、Revlimid)仿制药的利润损失,实现30%营业利润率。其中包括三项举措,一是借助业务中心、人工智能与数字化手段,减少层级,提升灵活性、速度与精准度,使一般及...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.